XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: capecitabine [Xeloda]|DRUG: Taxotere|DRUG: Herceptin (HER2-neu positive patients only)|DRUG: capecitabine [Xeloda]|DRUG: Taxotere
Sponsor: Hoffmann-La Roche